These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma. Lee JJ; Yeh JJ Surg Clin North Am; 2024 Oct; 104(5):939-950. PubMed ID: 39237169 [TBL] [Abstract][Full Text] [Related]
3. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Crawley AS; O'Kennedy RJ Expert Rev Mol Diagn; 2015; 15(10):1339-53. PubMed ID: 26394703 [TBL] [Abstract][Full Text] [Related]
5. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Maker AV; Carrara S; Jamieson NB; Pelaez-Luna M; Lennon AM; Dal Molin M; Scarpa A; Frulloni L; Brugge WR J Am Coll Surg; 2015 Feb; 220(2):243-53. PubMed ID: 25592469 [No Abstract] [Full Text] [Related]
6. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? Papadakos SP; Dedes N; Pergaris A; Gazouli M; Theocharis S Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408980 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for subtypes of pancreatic ductal adenocarcinoma. Venkatesan P Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444 [No Abstract] [Full Text] [Related]
8. Biomarkers, imaging and multifocality in intraductal papillary mucinous neoplasms: relevant for decision making? Ansari D; Aronsson L; Andersson R Future Oncol; 2017 Aug; 13(20):1751-1753. PubMed ID: 28831817 [No Abstract] [Full Text] [Related]
9. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303 [No Abstract] [Full Text] [Related]
11. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Kim S; Kang M; Lee S; Bae S; Han S; Jang JY; Park T Biomed Eng Online; 2014; 13 Suppl 2(Suppl 2):S5. PubMed ID: 25560450 [TBL] [Abstract][Full Text] [Related]
12. Role of non-coding RNAs in pancreatic cancer: the bane of the microworld. Tang YT; Xu XH; Yang XD; Hao J; Cao H; Zhu W; Zhang SY; Cao JP World J Gastroenterol; 2014 Jul; 20(28):9405-17. PubMed ID: 25071335 [TBL] [Abstract][Full Text] [Related]
13. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Mazur PK; Siveke JT Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467 [TBL] [Abstract][Full Text] [Related]
14. Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature. Wnuk J; Strzelczyk JK; Gisterek I Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982210 [TBL] [Abstract][Full Text] [Related]
15. Early detection of sporadic pancreatic cancer: summative review. Chari ST; Kelly K; Hollingsworth MA; Thayer SP; Ahlquist DA; Andersen DK; Batra SK; Brentnall TA; Canto M; Cleeter DF; Firpo MA; Gambhir SS; Go VL; Hines OJ; Kenner BJ; Klimstra DS; Lerch MM; Levy MJ; Maitra A; Mulvihill SJ; Petersen GM; Rhim AD; Simeone DM; Srivastava S; Tanaka M; Vinik AI; Wong D Pancreas; 2015 Jul; 44(5):693-712. PubMed ID: 25931254 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. Urayama S World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935 [TBL] [Abstract][Full Text] [Related]
17. Early detection of sporadic pancreatic cancer: strategic map for innovation--a white paper. Kenner BJ; Chari ST; Cleeter DF; Go VL Pancreas; 2015 Jul; 44(5):686-92. PubMed ID: 25938853 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas. Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C Front Immunol; 2021; 12():790661. PubMed ID: 34925373 [TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. Zhao L; Zhao H; Yan H BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660 [TBL] [Abstract][Full Text] [Related]
20. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]